Drug intelligence / Profile preview

PT403 + PT404

Development stage: Preclinical
Lead developer: Peptron
Modality: Peptides
Administration: Subcutaneous

Overview

PT403 + PT404 is a paired pipeline program developed by Peptron, a South Korean biotechnology company, utilizing their proprietary SmartDepot™ technology to create sustained-release formulations of semaglutide and tirzepatide. PT403 (SR-Semaglutide) is a long-acting Glucagon-like peptide 1 (GLP-1) receptor agonist, while PT404 (SR-Tirzepatide) is a dual GLP-1 and Gastric inhibitory polypeptide (GIP) receptor agonist. Both assets utilize biodegradable PLGA microspheres to enable once-monthly or once-every-two-months dosing, significantly extending the duration of action compared to current weekly injectables like Wegovy or Mounjaro. The program is currently in preclinical development for the treatment of Type 2 Diabetes and Obesity, with a Korea Phase 1 IND filing for PT403 planned for 2026.

Other names: SR-SemaglutideSR-TirzepatidePT403/PT404

Targets

GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)

Beyond the preview

Go deeper on PT403 + PT404.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PT403 + PT404.

Explore the full profile